These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Late-onset psoriatic arthritis in Japanese patients. Yamamoto T; Ohtsuki M; Sano S; Morita A; Igarashi A; Okuyama R; Kawada A J Dermatol; 2019 Feb; 46(2):169-170. PubMed ID: 30614050 [No Abstract] [Full Text] [Related]
10. Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs. Olivieri I; D'Angelo S Nat Rev Rheumatol; 2016 Feb; 12(2):76-8. PubMed ID: 26794864 [No Abstract] [Full Text] [Related]
11. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Coates LC; Gossec L; Ramiro S; Mease P; van der Heijde D; Smolen JS; Ritchlin C; Kavanaugh A Rheumatology (Oxford); 2017 Aug; 56(8):1251-1253. PubMed ID: 28077693 [No Abstract] [Full Text] [Related]
12. The role of methotrexate in psoriatic arthritis: what is the evidence? Ianculescu I; Weisman MH Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S94-7. PubMed ID: 26470718 [TBL] [Abstract][Full Text] [Related]
13. [The therapeutic benefits of systemic treatment of psoriatic arthritis? The example of golimumab in psoriatic arthritis]. Boulinguez S; Sibilia J Ann Dermatol Venereol; 2011 May; 138(5 Suppl 1):H11-5. PubMed ID: 21703459 [No Abstract] [Full Text] [Related]
14. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases]. Manger B; Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133 [No Abstract] [Full Text] [Related]
15. [Gold preparations in therapy of rheumatoid and psoriatic arthritis]. Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908 [No Abstract] [Full Text] [Related]
17. New drugs for peripheral joint psoriatic arthritis. Drug Ther Bull; 2006 Jan; 44(1):1-5. PubMed ID: 16425898 [TBL] [Abstract][Full Text] [Related]
18. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis. Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916 [TBL] [Abstract][Full Text] [Related]
19. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis. Reygaerts T; Mitrovic S; Fautrel B; Gossec L Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303 [TBL] [Abstract][Full Text] [Related]
20. Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development. Leijten EF; Radstake TR; McInnes IB; Jacobs JW Expert Rev Clin Immunol; 2019 May; 15(5):441-444. PubMed ID: 30729823 [No Abstract] [Full Text] [Related] [Next] [New Search]